VolitionRX (VNRX) Osake Kurssi
VolitionRX Kurssi
Viimeisten 13 vuoden aikana VolitionRXn liikevaihto kasvoi 30,4 % vuodessa ja ylsi 1,73 M USD:een. VolitionRXn nettomarginaali −1 352,2 % on noussut verrattuna −29 782,5 %:iin muutama vuosi sitten.
VolitionRX osakekurssi
VolitionRX liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset VolitionRX -osakkeesta
The business model of VolitionRX Ltd revolves around developing and commercializing innovative blood tests for the early detection of cancer and other diseases. VolitionRX Ltd focuses on developing and delivering cost-effective and minimally invasive diagnostic solutions to help healthcare professionals identify and treat diseases at their earliest stages. By utilizing its proprietary Nucleosomics® technology, VolitionRX Ltd aims to provide accurate and actionable information to improve patient outcomes and reduce healthcare costs. With its focus on research and innovation, VolitionRX Ltd strives to contribute to the advancement of personalized medicine and make a positive impact in the field of early disease detection.
VolitionRX Ltd is primarily active in the healthcare industry.
The main competitors of VolitionRX Ltd in the market include companies such as Exact Sciences Corporation, Guardant Health, Inc., and Oncocyte Corporation.
VolitionRX Ltd is a leading life sciences company specializing in developing innovative blood-based diagnostic tests. Founded in 2010, VolitionRX has rapidly established itself as a frontrunner in the early detection of cancer and other diseases. With a focus on epigenetics and nucleosome technologies, the company aims to provide affordable and accurate screening tools. VolitionRX's expertise lies in developing a comprehensive range of blood-based assays that can identify specific biomarkers associated with various diseases, offering potential breakthroughs in the medical field. Through a proactive and research-driven approach, VolitionRX is committed to revolutionizing the way diseases are diagnosed, offering hope for improved patient outcomes and overall healthcare.
VolitionRX Ltd has achieved several significant milestones. The company successfully completed multiple clinical trials for its innovative cancer diagnostic products, including the Nu.QTM platform. VolitionRX Ltd also received regulatory approvals and certifications, such as CE Marking for its products, allowing for commercialization in Europe. Additionally, the company formed strategic partnerships and collaborations with renowned research institutions and pharmaceutical companies, enhancing its exposure and potential market reach. Through its advancements, VolitionRX Ltd continues to revolutionize cancer diagnostics, improving patient outcomes and contributing to early disease detection.
VolitionRX Ltd is primarily present in the United States and Europe.
VolitionRX Ltd represents values of innovation, commitment to improving healthcare, and dedication to early cancer detection. The company's corporate philosophy revolves around developing cost-effective and non-invasive diagnostic tests to detect a wide range of cancers. VolitionRX Ltd strives to make a positive impact on patients' lives by providing accurate and timely screening methods that can potentially save lives. By harnessing the power of novel technologies, VolitionRX Ltd aims to deliver reliable diagnostic solutions and revolutionize the way cancer is detected and treated.
11 analyytikkoa arvioi tällä hetkellä VolitionRX-osaketta: 9 suosittaa ostoa, 2 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat VolitionRX-yhtiöltä 2,72 M USD liikevaihtoa ja −32,40 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla VolitionRX-osake noteerataan hintaan 0,20 EUR (0,23 USD).
VolitionRX-osake (VNRX) on listattuna 2 pörssissä, muun muassa: NYSE (VNRX).
VolitionRX Ltd is a Belgium-based company specializing in the development and marketing of blood tests for cancer diagnosis. The company's business model aims to bring innovative diagnostic technologies to the market to enable improved cancer detection. VolitionRX has different divisions such as product development, research and development, sales, and marketing to establish its products in the market. It specializes in the development of next-generation blood tests based on nucleosomes, which are protein complexes released during cell death. These protein complexes can be detected in the blood and indicate changes in the cell cycle that occur in cancer. VolitionRX has introduced its technology in various markets, including the US, European, and Asian markets. It has launched the Gastrointestinal Cancer Panel Test and the Lung Cancer Panel Test in the US and Europe, specifically designed for the early detection of stomach and lung cancer. The company has also initiated a program for the development of blood tests for the early detection of colorectal cancer. VolitionRX has obtained a patent for its technology and is working towards bringing its products to market. It has entered into several partnership agreements with other companies to sell and distribute its products. It has an agreement with Active Motif Inc. to distribute its products in Europe and an agreement with the Korean company Kubio Inc. to sell its products in Asia. VolitionRX has also developed a range of products for cancer research, including the NuQ Onco Test, which allows researchers to measure and examine specific changes in the cell cycle. VolitionRX's products have the potential to improve cancer diagnosis and early detection by offering cost-effective, non-invasive tests based on proprietary technology. The company aims to improve healthcare while being cost-effective in order to provide better treatment outcomes for patients. The company relies on an effective branding strategy to market its offerings. It regularly participates in industry events and has a strong online marketing focus on the benefits of its products. The company also collaborates closely with scientists and professionals to advance its research. Overall, VolitionRX's business model is focused on developing innovative diagnostic technologies to enable improved cancer early detection. It specializes in next-generation blood tests and works on various partnerships to sell and distribute its products. With its strong emphasis on developing cost-effective, non-invasive tests, VolitionRX has the potential to improve healthcare and provide better outcomes for patients.
odotettu liikevaihto VolitionRX on 2,72 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto VolitionRX on −173,06 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
VolitionRX:n hinta-voitto-suhde (P/E) on tällä hetkellä −0,01. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan VolitionRX-osakkeen arvostusta.
VolitionRX:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,44. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii VolitionRX-osakkeen arvostuskennuslukuna.
VolitionRX:n Eulpool-laatuscore on 4/10.
VolitionRX:n ISIN on US9286611077. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
VolitionRX:n WKN on A12B6K. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
VolitionRX:n ticker on VNRX. Tämä pörssinoteeraus käytetään VolitionRX-osakkeiden kauppaan pörssissä.
VolitionRX osake
VolitionRX vertaisryhmä
VolitionRX Ticker
VolitionRX FIGI
Kaikki tunnusluvut ja syvällinen analyysi VolitionRX:sta
Meidän osakeanalyysimme VolitionRX-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut VolitionRX:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: